{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:02:31Z","timestamp":1746849751729,"version":"3.40.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["63641015"],"award-info":[{"award-number":["63641015"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03909-9","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:17:40Z","timestamp":1746778660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prolonged time to treatment of biologics in inflammatory bowel disease: disparities from a retrospective study in a tertiary referral centre in the UK"],"prefix":"10.1186","volume":"25","author":[{"given":"Charlotte","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kamperidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Younge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lovesh","family":"Dyall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Rejee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naila","family":"Arebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"1","key":"3909_CR1","first-page":"32","volume":"18","author":"GR Lichtenstein","year":"2022","unstructured":"Lichtenstein GR, Shahabi A, Seabury SA, Lakdawalla DN, Espinosa OD, Green S, Brauer M, Baldassano RN. Increased Lifetime Risk of Intestinal Complications and Extraintestinal Manifestations in Crohn\u2019s Disease and Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2022;18(1):32\u201343.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"3909_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"KT Park","year":"2020","unstructured":"Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, Kim SC, Lawton RC, Murphy SM, Regueiro M, Rubin DT, Engel-Nitz NM, Heller CA. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn\u2019s & Colitis Foundation. Inflamm Bowel Dis. 2020;26(1):1\u201310.","journal-title":"Inflamm Bowel Dis"},{"key":"3909_CR3","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.crphar.2022.100104","volume":"3","author":"P Juillerat","year":"2022","unstructured":"Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillemoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom? Curr Res Pharmacol Drug Discov. 2022;3:100104.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"12","key":"3909_CR4","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/ibd\/izz059","volume":"25","author":"DR Berg","year":"2019","unstructured":"Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(12):1896\u2013905.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"3909_CR5","doi-asserted-by":"publisher","first-page":"otab064","DOI":"10.1093\/crocol\/otab064","volume":"3","author":"GJ Mantzaris","year":"2021","unstructured":"Mantzaris GJ, Zeglinas C, Theodoropoulou A, Koutroubakis I, Orfanoudaki E, Katsanos K, Christodoulou D, Michalopoulos G, Tzouvala M, Moschovis D, Michopoulos S, Zampeli E, Soufleris K, Ilias A, Chatzievangelinou C, Kyriakakis A, Antachopoulou K, Karmiris K. The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn\u2019s Disease With Poor Prognostic Factors: The MODIFY Study. Crohns Colitis 360. 2021;3(4):otab064.","journal-title":"Crohns Colitis 360."},{"issue":"3","key":"3909_CR6","doi-asserted-by":"publisher","first-page":"e2021052501","DOI":"10.1542\/peds.2021-052501","volume":"149","author":"BD Constant","year":"2022","unstructured":"Constant BD, de Zoeten EF, Stahl MG, Vajravelu RK, Lewis JD, Fennimore B, Gerich ME, Scott FI. Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics. 2022;149(3):e2021052501.","journal-title":"Pediatrics."},{"key":"3909_CR7","unstructured":"What are health inequalities? : The King\u2019s Fund; 2022 [Available from: https:\/\/www.kingsfund.org.uk\/publications\/what-are-health-inequalities."},{"key":"3909_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/gidisord2020015","volume":"22","author":"A Farrukh","year":"2020","unstructured":"Farrukh A, Mayberry J. Apparent Disparities in Hospital Admission and Biologic Use in the Management of Inflammatory Bowel Disease between 2014\u20132018 in Some Black and Ethnic Minority (BEM) Populations in England. Gastrointestinal Disord. 2020;22:144\u201351.","journal-title":"Gastrointestinal Disord."},{"issue":"2","key":"3909_CR9","first-page":"187","volume":"35","author":"T Raine","year":"2021","unstructured":"Raine T, Gkini MA, Irving PM, Kaul A, Korendowych E, Laws P, Foulkes AC. Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists. Rheumatol Gastroenterol BioDrugs. 2021;35(2):187\u201399.","journal-title":"Rheumatol Gastroenterol BioDrugs"},{"issue":"6","key":"3909_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.cgh.2014.11.020","volume":"13","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheaume RL, Sandler RS. Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol. 2015;13(6):1197\u2013200.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3909_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/gastro\/gox005","volume":"6","author":"S Singh","year":"2018","unstructured":"Singh S, Chowdhry M, Umar S, Bilal M, Clarke K. Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. Gastroenterol Rep (Oxf). 2018;6(1):61\u20134.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"Suppl 1","key":"3909_CR12","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.2105\/AJPH.2010.300062","volume":"101","author":"PA Braveman","year":"2011","unstructured":"Braveman PA, Kumanyika S, Fielding J, Laveist T, Borrell LN, Manderscheid R, Troutman A. Health disparities and health equity: the issue is justice. Am J Public Health. 2011;101(Suppl 1):S149\u201355.","journal-title":"Am J Public Health"},{"issue":"7","key":"3909_CR13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ibd.20121","volume":"13","author":"MD Kappelman","year":"2007","unstructured":"Kappelman MD, Bousvaros A, Hyams J, Markowitz J, Pfefferkorn M, Kugathasan S, Rosh J, Otley A, Mack D, Griffiths A, Evans J, Grand R, Langton C, Kleinman K, Finkelstein JA. Intercenter variation in initial management of children with Crohn\u2019s disease. Inflamm Bowel Dis. 2007;13(7):890\u20135.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"3909_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11894-017-0581-x","volume":"19","author":"SK Berry","year":"2017","unstructured":"Berry SK, Siegel CA, Melmed GY. Quality Improvement Initiatives in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2017;19(8):41.","journal-title":"Curr Gastroenterol Rep"},{"issue":"Suppl 3","key":"3909_CR15","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, group IBDgec, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106.","journal-title":"Gut."},{"issue":"6","key":"3909_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/ibd\/izac161","volume":"29","author":"R Greywoode","year":"2023","unstructured":"Greywoode R, Petralia F, Ullman TA, Frederic Colombel J, Ungaro RC. Racial Difference in Efficacy of Golimumab in Ulcerative Colitis. Inflamm Bowel Dis. 2023;29(6):843\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"3909_CR17","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/ibd\/izab237","volume":"28","author":"A Booth","year":"2022","unstructured":"Booth A, Ford W, Brennan E, Magwood G, Forster E, Curran T. Towards Equitable Surgical Management of Inflammatory Bowel Disease: A Systematic Review of Disparities in Surgery for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022;28(9):1405\u201319.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"3909_CR18","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/MCG.0000000000001204","volume":"54","author":"A Galoosian","year":"2020","unstructured":"Galoosian A, Rezapour M, Liu B, Bhuket T, Wong RJ. Race\/Ethnicity-specific Disparities in In-Hospital Mortality and Hospital Charges Among Inflammatory Bowel Disease-related Hospitalizations in the United States. J Clin Gastroenterol. 2020;54(7):e63\u201372.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3909_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, Gonzalez-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4\u201322.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3909_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Spinelli A, Panis Y, Doherty G. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2\u201317.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"3909_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","volume":"156","author":"CW Ko","year":"2019","unstructured":"Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, American Gastroenterological Association Institute Clinical Guidelines C. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterol. 2019;156(3):748\u201364.","journal-title":"Gastroenterol."},{"issue":"7","key":"3909_CR22","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP, American Gastroenterological Association Institute Clinical Guidelines C. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease. Gastroenterology. 2021;160(7):2496\u2013508.","journal-title":"Gastroenterology."},{"issue":"5","key":"3909_CR23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","volume":"148","author":"B Bressler","year":"2015","unstructured":"Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B, Toronto Ulcerative Colitis Consensus G. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035-58 e3.","journal-title":"Gastroenterology."},{"issue":"3","key":"3909_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/jcag\/gwz019","volume":"2","author":"R Panaccione","year":"2019","unstructured":"Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn\u2019s Disease. J Can Assoc Gastroenterol. 2019;2(3):e1\u201334.","journal-title":"J Can Assoc Gastroenterol"},{"issue":"3","key":"3909_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/flgastro-2019-101260","volume":"11","author":"R Kapasi","year":"2020","unstructured":"Kapasi R, Glatter J, Lamb CA, Acheson AG, Andrews C, Arnott ID, Barrett KJ, Bell G, Bhatnagar G, Bloom S, Brookes MJ, Brown SR, Burch N, Burman A, Crook K, Cummings JF, Davies J, Demick A, Epstein J, Faiz O, Feakins R, Fletcher M, Garrick V, Jaffray B, Johnson M, Keetarut K, Limdi J, Meade U, Muhammed R, Murdock A, Posford N, Rowse G, Shaw I, St Clair Jones A, Taylor S, Weaver S, Younge L, Hawthorne AB. Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. Frontline Gastroenterol. 2020;11(3):178\u201387.","journal-title":"Frontline Gastroenterol."},{"issue":"Supplement_1","key":"3909_CR26","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1093\/ecco-jcc\/jjy222.298","volume":"13","author":"A McCulloch","year":"2019","unstructured":"McCulloch A, Abbas M, Bannaga A, McDowell P, Bate T, Kandathil M, Shah J, Sharif Q, Love M, Sharma N, Cooney R. P174 System delays have real consequences: Impact of timing of biologic commencement on inflammatory bowel disease patient response. J Crohn\u2019s Colitis. 2019;13(Supplement_1):S176-S.","journal-title":"J Crohn's Colitis."},{"issue":"Suppl 4","key":"3909_CR27","first-page":"A96","volume":"70","author":"E Liu","year":"2021","unstructured":"Liu E, Jatale R, DeSilva D, Hussain S, Danso Y, Sabine J, Taylor J, Sattar H, Smith P, Subramanian S, Limdi J. PMO-39 Factors influencing delays in biologic initiation in inflammatory bowel disease. Gut. 2021;70(Suppl 4):A96\u20137.","journal-title":"Gut"},{"issue":"10","key":"3909_CR28","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/ibd\/izad012","volume":"29","author":"DK Choi","year":"2023","unstructured":"Choi DK, Cohen NA, Choden T, Cohen RD, Rubin DT. Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023;29(10):1658\u201361.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3909_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12876-021-01857-8","volume":"21","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Newton PD, Ojo O, Dibley L. Experiences of ethnic minority patients who are living with a primary chronic bowel condition: a systematic scoping review with narrative synthesis. BMC Gastroenterol. 2021;21(1):322.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"3909_CR30","first-page":"e15270","volume":"13","author":"H Selvaskandan","year":"2021","unstructured":"Selvaskandan H, Moorthy A. An Ethnic Variation in the Acceptance of Biological Disease-Modifying Therapies: A University Hospital Experience. Cureus. 2021;13(5):e15270.","journal-title":"Cureus"},{"issue":"11","key":"3909_CR31","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s10620-019-05504-x","volume":"64","author":"C Le Berre","year":"2019","unstructured":"Le Berre C, Danese S, Peyrin-Biroulet L. Timely Use of Biologics in Early Crohn\u2019s Disease: The Return of \u201cHit Hard and Early\u201d? Dig Dis Sci. 2019;64(11):3035\u20137.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3909_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s10620-018-5159-4","volume":"64","author":"S Cohen-Mekelburg","year":"2019","unstructured":"Cohen-Mekelburg S, Gold S, Schneider Y, Dennis M, Oromendia C, Yeo H, Michelassi F, Scherl E, Steinlauf A. Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn\u2019s Disease Patients. Dig Dis Sci. 2019;64(1):196\u2013203.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3909_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2500\/aap.2021.42.200101","volume":"42","author":"GJ Dudiak","year":"2021","unstructured":"Dudiak GJ, Popyack J, Grimm C, Tyson S, Solic J, Ishmael FT. Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations. Allergy Asthma Proc. 2021;42(1):65\u201371.","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"3909_CR34","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.jacig.2022.10.007","volume":"2","author":"E Sehanobish","year":"2023","unstructured":"Sehanobish E, Ye K, Imam K, Sariahmed K, Kurian J, Patel J, Belletti D, Chung Y, Jariwala S, White A, Jerschow E. Elaborate biologic approval process delays care of patients with moderate-to-severe asthma. J Allergy Clin Immunol Glob. 2023;2(2):100076.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"5","key":"3909_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jaip.2021.12.027","volume":"10","author":"CM Porsbjerg","year":"2022","unstructured":"Porsbjerg CM, Menzies-Gow AN, Tran TN, Murray RB, Unni B, Audrey Ang SL, Alacqua M, Al-Ahmad M, Al-Lehebi R, Altraja A, Belevskiy AS, Bjornsdottir US, Bourdin A, Busby J, Canonica GW, Christoff GC, Cosio BG, Costello RW, FitzGerald JM, Fonseca JA, Hansen S, Heaney LG, Heffler E, Hew M, Iwanaga T, Jackson DJ, Kocks JWH, Kallieri M, Bruce Ko HK, Koh MS, Larenas-Linnemann D, Lehtimaki LA, Loukides S, Lugogo N, Maspero J, Papaioannou AI, Perez-de-Llano L, Pitrez PM, Popov TA, Rasmussen LM, Rhee CK, Sadatsafavi M, Schmid J, Siddiqui S, Taille C, Taube C, Torres-Duque CA, Ulrik C, Upham JW, Wang E, Wechsler ME, Bulathsinhala L, Carter V, Chaudhry I, Eleangovan N, Hosseini N, Rowlands MA, Price DB, van Boven JFM. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. J Allergy Clin Immunol Pract. 2022;10(5):1202-16 e23.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"12","key":"3909_CR36","doi-asserted-by":"publisher","first-page":"e1917053","DOI":"10.1001\/jamanetworkopen.2019.17053","volume":"2","author":"M Tatangelo","year":"2019","unstructured":"Tatangelo M, Tomlinson G, Paterson JM, Ahluwalia V, Kopp A, Gomes T, Bansback N, Bombardier C. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage. JAMA Netw Open. 2019;2(12):e1917053.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3909_CR37","doi-asserted-by":"publisher","first-page":"jjae186","DOI":"10.1093\/ecco-jcc\/jjae186","volume":"19","author":"S Balarajah","year":"2025","unstructured":"Balarajah S, Martinez-Gili L, Alexander JL, Mullish BH, Perry RW, Li JV, Marchesi JR, Parkes M, Orchard TR, Hicks LC, Williams HRT. Diverse Phenotypes, Consistent Treatment: A Study of 30 997 South Asian and White Inflammatory Bowel Disease Patients Using the UK Inflammatory Bowel Disease BioResource. J Crohns Colitis. 2025;19(1):jjae186.","journal-title":"J Crohns Colitis."},{"issue":"5","key":"3909_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Probert CS, Raine T, Saich R, Seward A, Sharpstone D, Smith MA, Subramanian S, Upponi SS, Wiles A, Williams HRT, van den Brink GR, Vermeire S, Jairath V, D\u2019Haens GR, McKinney EF, Lyons PA, Lindsay JO, Kennedy NA, Smith KGC, Parkes M, Group PS. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):415\u201327.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"5","key":"3909_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.gastro.2024.01.041","volume":"166","author":"R Lujan","year":"2024","unstructured":"Lujan R, Buchuk R, Focht G, Yogev D, Greenfeld S, Ben-Tov A, Weisband YL, Lederman N, Matz E, Ben Horin S, Dotan I, Nevo D, Turner D. Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort. Gastroenterol. 2024;166(5):815-25 e22.","journal-title":"Gastroenterol."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03909-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03909-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03909-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:17:42Z","timestamp":1746778662000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03909-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3909"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03909-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not report on experiments on humans and\/or the use of human tissue samples. It was conducted in accordance with the Declaration of Helsinki, Health Research Authority (HRA) in the United Kingdom and Good Clinical Practice (GCP) guidelines. Institutional review board (IRB) approval was obtained from London North West University Healthcare NHS Trust in the United Kingdom (evaluation reference number SE21\/003) who waived the need for ethical approval and patient consent as anonymised retrospective EHR was used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We did not use any personally identifiable patient data and therefore patient consent was not required for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.W. has received sponsor fees with Dr Falk Pharma. P.B. has no conflicts of interest. N.K. has received speaker fees from Abbvie, Janssen and Takeda in addition to sponsor fees from Tillots, Takeda and Janssen. R.M has received speaker fees from Abbvie. L.Y. has received lecture, advisory board and personal fees from Abbvie, Janssen and Takeda. L.D. has received speaker fees from Dr Falk Pharma and Abbvie. K.Y. has received sponsor and speaker fees from Abbvie. C.R. has no conflicts of interest. N.A. has received grant support from Janssen in addition to lecture, advisory and personal fees from Takeda, Janssen, Galapagos and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"352"}}